Article ; Online: EEG Biomarkers to Predict Response to Sertraline and Placebo Treatment in Major Depressive Disorder.
IEEE transactions on bio-medical engineering
2023 Volume 70, Issue 3, Page(s) 909–919
Abstract: Objective: Major depressive disorder (MDD) is a persistent psychiatric condition, and the leading cause of disability, affecting up to 5% of the population worldwide. Antidepressant medications (ADMs) are often the first-line treatment for MDD, but it ... ...
Abstract | Objective: Major depressive disorder (MDD) is a persistent psychiatric condition, and the leading cause of disability, affecting up to 5% of the population worldwide. Antidepressant medications (ADMs) are often the first-line treatment for MDD, but it may take the clinician months of "trial and error" to find an effective ADM for a particular patient. Therefore, identification of predictive biomarkers that can be used to accurately determine the effectiveness of a specific treatment for an individual patient is extremely valuable. Method: Using resting EEG data, we develop a machine learning algorithm (MLA) that searches for connectivity patterns within an individual's EEG signal that are predictive of the probability of responding to the antidepressant Sertraline or Placebo. The MLA has two steps: 1) Directed phase lag index (DPLI), a measure of phase synchronization between brain regions, that is not sensitive to volume conduction is applied to resting-state EEG data, 2) the resulting DPLI matrix is searched for a pattern set of features that can be used to successfully predict the response to Sertraline or Placebo. Results: Our MLA predicted response to Sertraline (N = 105) or Placebo (N = 119) with more than 80% accuracy. Conclusion: Our findings suggest that feature patterns selected from a DPLI matrix may be predictive of response to Sertraline and to Placebo. Significance: The proposed MLA may provide an inexpensive, non-invasive, and readily available tool that clinicians may use to enhance treatment effectiveness, accelerate time to recovery, reduce personal suffering, and decrease treatment costs. |
---|---|
MeSH term(s) | Humans ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Biomarkers ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Major/epidemiology ; Depressive Disorder, Major/psychology ; Electroencephalography/methods ; Sertraline/therapeutic use |
Chemical Substances | Antidepressive Agents ; Biomarkers ; Sertraline (QUC7NX6WMB) |
Language | English |
Publishing date | 2023-02-17 |
Publishing country | United States |
Document type | Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 160429-6 |
ISSN | 1558-2531 ; 0018-9294 |
ISSN (online) | 1558-2531 |
ISSN | 0018-9294 |
DOI | 10.1109/TBME.2022.3204861 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 425: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.